/
EWTX
$40.92-$0.54 (-1.30%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$4.5B
108M shares
52-week range
$12.30 – $43.93
90% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$19.59
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $123.0K | $185.0K | $0 | $0 | $0 | $0 | $2.3M |
| Gross profit | −$123.0K | −$185.0K | $0 | $0 | $0 | $0 | −$2.3M |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $8.6M | $14.8M | $32.2M | $54.0M | $90.9M | $127.0M | $151.4M |
| Operating income | −$9.9M | −$17.2M | −$43.2M | −$71.7M | −$114.4M | −$158.8M | −$191.4M |
| EBITDA | −$9.8M | −$17.0M | −$42.5M | −$63.1M | −$98.4M | −$131.5M | −$165.5M |
| Net income | −$9.5M | −$17.1M | −$42.8M | −$67.6M | −$100.2M | −$133.8M | −$167.8M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -0.19 | -0.35 | -0.86 | -1.26 | -1.57 | -1.45 | -1.63 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-1.96 | $-2.24–$-1.75 | 6 |
| 2027 | $41M | $-1.63 | $-2.46–$-0.34 | 7 |
| 2028 | $67M | $-1.72 | $-2.76–$-0.15 | 6 |
| 2029 | $257M | $0.02 | $0.00–$0.05 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.50
Price
$40.92
Implied downside
-99%
Peer comparison
Edgewise Therapeutics, Inc. Common Stock
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
www.edgewisetx.com- Employees
- 154
- IPO / List date
- Mar 26, 2021
- HQ
- BOULDER, CO
Held by traders on TradeandTell
No one on the platform currently holds EWTX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-09-30 | 27,465 | $733.0K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded EWTX yet.
